JPWO2022248940A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022248940A5
JPWO2022248940A5 JP2023573437A JP2023573437A JPWO2022248940A5 JP WO2022248940 A5 JPWO2022248940 A5 JP WO2022248940A5 JP 2023573437 A JP2023573437 A JP 2023573437A JP 2023573437 A JP2023573437 A JP 2023573437A JP WO2022248940 A5 JPWO2022248940 A5 JP WO2022248940A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
agents
agent
antibody
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023573437A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024521861A (ja
JP2024521861A5 (https=
Publication date
Priority claimed from US17/334,158 external-priority patent/US20220389104A1/en
Application filed filed Critical
Publication of JP2024521861A publication Critical patent/JP2024521861A/ja
Publication of JPWO2022248940A5 publication Critical patent/JPWO2022248940A5/ja
Publication of JP2024521861A5 publication Critical patent/JP2024521861A5/ja
Pending legal-status Critical Current

Links

JP2023573437A 2021-05-28 2022-05-27 抗ｃｄ１２７剤を投与することによってｃｄ１２７陽性がんを処置する方法 Pending JP2024521861A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17/334,158 2021-05-28
US17/334,158 US20220389104A1 (en) 2021-05-28 2021-05-28 Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent
PCT/IB2022/000365 WO2022248940A1 (en) 2021-05-28 2022-05-27 Method for treating cd127-positive cancers by administering an anti-cd127 agent

Publications (3)

Publication Number Publication Date
JP2024521861A JP2024521861A (ja) 2024-06-04
JPWO2022248940A5 true JPWO2022248940A5 (https=) 2025-06-03
JP2024521861A5 JP2024521861A5 (https=) 2025-06-03

Family

ID=82701915

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023573437A Pending JP2024521861A (ja) 2021-05-28 2022-05-27 抗ｃｄ１２７剤を投与することによってｃｄ１２７陽性がんを処置する方法

Country Status (5)

Country Link
US (1) US20220389104A1 (https=)
EP (1) EP4347043A1 (https=)
JP (1) JP2024521861A (https=)
CN (1) CN117769435A (https=)
WO (1) WO2022248940A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115925955B (zh) * 2022-12-30 2025-09-26 浙江正熙生物技术有限公司 一种抗cd127抗体及其制备方法和应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618829A (en) 1993-01-28 1997-04-08 Mitsubishi Chemical Corporation Tyrosine kinase inhibitors and benzoylacrylamide derivatives
AU691820B2 (en) 1993-07-15 1998-05-28 Cancer Research Campaign Technology Limited Prodrugs of protein tyrosine kinase inhibitors
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
US5639757A (en) 1995-05-23 1997-06-17 Pfizer Inc. 4-aminopyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors
HU228446B1 (en) 1996-04-12 2013-03-28 Warner Lambert Co Kinazoline derivatives as irreversible inhibitors of protein-kinase, pharmaceutical compositions containing these compounds and use thereof
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
US6100254A (en) 1997-10-10 2000-08-08 Board Of Regents, The University Of Texas System Inhibitors of protein tyrosine kinases
US6740665B1 (en) 1999-02-10 2004-05-25 Ramachandran Murali Tyrosine kinase inhibitors and methods of using the same
US6245759B1 (en) 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2001000214A1 (en) 1999-06-30 2001-01-04 Merck & Co., Inc. Src kinase inhibitor compounds
JP2003503351A (ja) 1999-06-30 2003-01-28 メルク エンド カムパニー インコーポレーテッド Ｓｒｃキナーゼ阻害化合物
AU5636900A (en) 1999-06-30 2001-01-31 Merck & Co., Inc. Src kinase inhibitor compounds
DE60023926T2 (de) 1999-09-10 2006-07-20 Merck & Co., Inc. Tyrosin kinase inhibitoren
AU778042B2 (en) 1999-10-19 2004-11-11 Merck & Co., Inc. Tyrosine kinase inhibitors
HRP20020349A2 (en) 1999-10-19 2004-02-29 Merck & Co Inc Tyrosine kinase inhibitors
US6794393B1 (en) 1999-10-19 2004-09-21 Merck & Co., Inc. Tyrosine kinase inhibitors
US6313138B1 (en) 2000-02-25 2001-11-06 Merck & Co., Inc. Tyrosine kinase inhibitors
US6420382B2 (en) 2000-02-25 2002-07-16 Merck & Co., Inc. Tyrosine kinase inhibitors
ATE316088T1 (de) 2001-06-22 2006-02-15 Merck & Co Inc Tyrosin-kinase inhibitoren
WO2003011836A1 (en) 2001-08-01 2003-02-13 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003020276A1 (en) 2001-08-30 2003-03-13 Merck & Co., Inc. Tyrosine kinase inhibitors
US7908091B2 (en) 2006-03-17 2011-03-15 Prometheus Laboratories Inc. Methods of predicting and monitoring tyrosine kinase inhibitor therapy
MX339083B (es) * 2010-01-28 2016-04-01 Glaxo Group Ltd Proteinas de enlace a cd127.
EP2955196A1 (en) * 2014-06-10 2015-12-16 Effimune Antibodies directed against CD127
WO2016059220A1 (en) * 2014-10-16 2016-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Tcr-activating agents for use in the treatment of t-all
WO2016109415A1 (en) * 2014-12-30 2016-07-07 Celgene Corporation Anti-cd47 antibodies and uses thereof
WO2017005919A1 (en) * 2015-07-08 2017-01-12 Biomedical Research Foundation Of The Academy Of Athens Novel compounds for use in treating or preventing cancerous diseases
EP3355875B1 (en) * 2015-10-01 2021-09-29 Gilead Sciences, Inc. Combination of a btk inhibitor and a checkpoint inhibitor for treating cancers
AU2016335750B2 (en) * 2015-10-07 2023-05-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services IL-7R-alpha specific antibodies for treating acute lymphoblastic leukemia
WO2017149394A1 (en) * 2016-02-29 2017-09-08 Ose Immunotherapeutics Non-antagonistic antibodies directed against the alpha chain of the il7 receptor extracellular domain and use thereof in cancer treatment
IL301786B2 (en) * 2016-10-28 2025-09-01 Morphosys Ag Combination of anti-CD19 antibody with BCL-2 inhibitor and their uses
DK3551664T3 (da) 2016-12-09 2021-05-03 Ose Immunotherapeutics Antistoffer og polypeptider rettet mod cd127
US11008395B2 (en) 2019-01-22 2021-05-18 Bristol Myers-Squibb Company Antibodies against IL-7R alpha subunit and uses thereof

Similar Documents

Publication Publication Date Title
JP7551693B2 (ja) ＮＫｐ４６結合タンパク質の可変領域
JP7323513B2 (ja) 抗４－１ｂｂ抗体とその作製及び使用方法
US12528876B2 (en) CD73 blocking antibodies
CN108290948B (zh) 抗-cd47抗体及使用方法
CA2599734C (en) Humanized l243 antibodies
JP2019519208A (ja) 抗ｃｔｌａ−４抗体
CN116249548A (zh) 用于治疗多发性骨髓瘤的方法
KR20130028055A (ko) Ｃｄ １２７ 결합 단백질
AU2016355206A1 (en) Novel anti-EMR2 antibodies and methods of use
JP2023536627A (ja) Ｅｇｆｒを標的とする抗体およびその使用
EP3122780A2 (en) Antibodies that bind human cannabinoid 1 (cb1) receptor
JP2024026170A (ja) 癌を処置するための組成物及び方法
JP6914283B2 (ja) ヒトのがんを治療するための特異的抗ｃｄ３８抗体
CN118317975A (zh) 靶向baff-r的抗体及其用途
CN116829186A (zh) 多特异性抗体及其用途
IL258337B2 (en) Antibodies that bind human cannabinoid receptor 1
JP7558534B2 (ja) Ｃｄ１３７アゴニスト性抗体とその使用
CA3023088A1 (en) Novel anti-tnfrsf21 antibodies and methods of use
US20240270865A1 (en) Cancer treatment methods using anti-cd73 antibodies
CN121712802A (zh) 抗b7-h3抗体及其用途
JPWO2022248940A5 (https=)
CA3125451C (en) Cd137 agonist antibodies and uses thereof
RU2819204C2 (ru) Антитела, блокирующие cd73
WO2025094085A1 (en) Combination regimens for treating multiple myeloma
WO2024148208A1 (en) Antibodies specifically recognizing tnfr2 and compositions and uses thereof